Kirsty Rizzo1, Kevin Vella2, Daniel Zammit2, Peter Gatt3, Charlie Grima3, Monique Borg Inguanez4, Jurgen Gerada5, Pierre Ellul5, Mario Vassallo5, Neville Azzopardi5, James Pocock5, Alex Gatt2,6. 1. Faculty of Health Sciences, University of Malta, Tal-Qroqq, Msida, Malta. 2. Coagulation Laboratory, Department of Pathology, "Mater Dei" Hospital, Msida, Malta. 3. Clinical Perfusion Services, Department of Cardiac Surgery, "Mater Dei" Hospital, Msida, Malta. 4. Department of Statistics and Operations Research, University of Malta, Tal-Qroqq, Msida, Malta. 5. Division of Gastroenterology, "Mater Dei" Hospital, Msida, Malta. 6. Department of Pathology, University of Malta, Tal-Qroqq, Msida, Malta.
Abstract
BACKGROUND: Fibrinogen is produced in the liver and tends to be reduced in liver cirrhosis. Quantitative and qualitative tests exist to measure fibrinogen. We aimed to validate the functional fibrinogen thromboelastography assay (FF-TEG) and propose a new model to estimate fibrinogen levels via the Clauss method (Clauss) using data from a prothrombin time-derived fibrinogen assay (PT-Fg) in patients with liver cirrhosis. MATERIALS AND METHODS: Clauss, PT-Fg, fibrinogen antigen (Fib-Ag) and FF-TEG were studied in 55 patients with liver cirrhosis (26 with Child-Turcotte-Pugh [CTP]-A disease, 14 with CTP-B and 15 CTP-C) and 20 healthy individuals. RESULTS: The results of all four assays correlated strongly with each other, but gave significantly different mean levels in all cohorts. PT-Fg gave the highest levels whereas the Clauss gave the lowest levels. The FF-TEG performed well with results which were in between the Clauss and the PT-Fg. Significant differences were only observed between CTP-A and CTP-C for the Clauss, PT-Fg and Fib-Ag but not functional fibrinogen level. We devised a simple linear regression model in order to estimate Clauss from the PT-Fg. DISCUSSION: The results of the FF-TEG correlate well with those of routine fibrinogen assays in patients with liver cirrhosis. However, the FF-TEG assay does not discriminate between early and late stages of disease, pointing to a preserved fibrin clot strength in cirrhosis. Through linear regression models, fibrinogen levels can be accurately estimated using the Clauss method based on fibrinogen levels obtained in the cheaper PT-Fg.
BACKGROUND:Fibrinogen is produced in the liver and tends to be reduced in liver cirrhosis. Quantitative and qualitative tests exist to measure fibrinogen. We aimed to validate the functional fibrinogen thromboelastography assay (FF-TEG) and propose a new model to estimate fibrinogen levels via the Clauss method (Clauss) using data from a prothrombin time-derived fibrinogen assay (PT-Fg) in patients with liver cirrhosis. MATERIALS AND METHODS: Clauss, PT-Fg, fibrinogen antigen (Fib-Ag) and FF-TEG were studied in 55 patients with liver cirrhosis (26 with Child-Turcotte-Pugh [CTP]-A disease, 14 with CTP-B and 15 CTP-C) and 20 healthy individuals. RESULTS: The results of all four assays correlated strongly with each other, but gave significantly different mean levels in all cohorts. PT-Fg gave the highest levels whereas the Clauss gave the lowest levels. The FF-TEG performed well with results which were in between the Clauss and the PT-Fg. Significant differences were only observed between CTP-A and CTP-C for the Clauss, PT-Fg and Fib-Ag but not functional fibrinogen level. We devised a simple linear regression model in order to estimate Clauss from the PT-Fg. DISCUSSION: The results of the FF-TEG correlate well with those of routine fibrinogen assays in patients with liver cirrhosis. However, the FF-TEG assay does not discriminate between early and late stages of disease, pointing to a preserved fibrin clot strength in cirrhosis. Through linear regression models, fibrinogen levels can be accurately estimated using the Clauss method based on fibrinogen levels obtained in the cheaper PT-Fg.
Authors: Ivo Fluger; Katerina Maderova; Martin Simek; Roman Hajek; Jana Zapletalova; Vladimir Lonsky Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2011-06-28 Impact factor: 1.245
Authors: Gia A DeAngelis; Rachita Khot; Ziv J Haskal; Hillary S Maitland; Patrick G Northup; Neeral L Shah; Stephen H Caldwell Journal: J Vasc Interv Radiol Date: 2016-08-29 Impact factor: 3.464
Authors: Jeffrey N Harr; Ernest E Moore; Arsen Ghasabyan; Theresa L Chin; Angela Sauaia; Anirban Banerjee; Christopher C Silliman Journal: Shock Date: 2013-01 Impact factor: 3.454
Authors: G C G Hugenholtz; F Macrae; J Adelmeijer; S Dulfer; R J Porte; T Lisman; R A S Ariëns Journal: J Thromb Haemost Date: 2016-03-07 Impact factor: 5.824